Bacteriophages, as the most dominant and diverse entities in the universe, have the potential to be one of the most promising therapeutic agents. The emergence of multidrug-resistant bacteria and the antibiotic crisis in the last few decades have resulted in a renewed interest in phage therapy. Furthermore, bacteriophages, with the capacity to rapidly infect and overcome bacterial resistance, have demonstrated a sustainable approach against bacterial pathogens-particularly in biofilm. Biofilm, as complex microbial communities located at interphases embedded in a matrix of bacterial extracellular polysaccharide substances (EPS), is involved in health issues such as infections associated with the use of biomaterials and chronic infections by multidrug resistant bacteria, as well as industrial issues such as biofilm formation on stainless steel surfaces in food industry and membrane biofouling in water and wastewater treatment processes. In this paper, the most recent studies on the potential of phage therapy using natural and genetically-modified lytic phages and their associated enzymes in fighting biofilm development in various fields including engineering, industry, and medical applications are reviewed. Phage-mediated prevention approaches as an indirect phage therapy strategy are also explored in this review. In addition, the limitations of these approaches and suggestions to overcome these constraints are discussed to enhance the efficiency of phage therapy process. Finally, future perspectives and directions for further research towards a better understanding of phage therapy to control biofilm are recommended.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s11274-016-2009-4 | DOI Listing |
Clin Transl Med
January 2025
Department of General Surgery (Colorectal Surgery), The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
Background: Immunotherapy is beneficial for some colorectal cancer (CRC) patients, but immunosuppressive networks limit its effectiveness. Cancer-associatedfibroblasts (CAFs) are significant in immune escape and resistance toimmunotherapy, emphasizing the urgent need for new treatment strategies.
Methods: Flow cytometric, Western blotting, proteomics analysis, analysis of public database data, genetically modified cell line models, T cell coculture, crystal violetstaining, ELISA, metabonomic and clinical tumour samples were conducted to assess the role of EDEM3 in immune escape and itsmolecular mechanisms.
BMC Res Notes
January 2025
Department of Microbiology and Immunology, Faculty of Pharmacy, Damanhour University, Damanhour, Egypt.
Objectives: The aim of this study is to screen for, isolate and characterize a bacteriophage designated ɸEcM-vB1 with confirmed lytic activity against multidrug-resistant (MDR) E. coli. Methods done in this research are bacteriophage isolation, purification, titer determination, bacteriophage morphology, host range determination, bacteriophage latent period and burst size determination, genomic analysis by restriction enzymes, and bacteriophage total protein content determination.
View Article and Find Full Text PDFCancer Immunol Immunother
January 2025
Public Center of Experimental Technology, The School of Basic Medical Sciences, Southwest Medical University, Luzhou, 646000, Sichuan Province, China.
Although immune checkpoint inhibitors have changed the treatment paradigm for non-small cell lung cancer (NSCLC), not all patients benefit from them. Therefore, there is an urgent need to explore novel immune checkpoint inhibitors. Neuropilin-1 (Nrp-1) is a unique immune checkpoint capable of exerting antitumor effects through CD8 T cells.
View Article and Find Full Text PDFJ Virol
December 2024
College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, Beijing, China.
J Glob Antimicrob Resist
December 2024
Pôle de Microbiologie, Institut Pasteur de Dakar, Sénégal; Faculté de Médecine, Pharmacie et Odontostomatologie, Université Cheikh Anta Diop, Dakar, Sénégal.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!